Back to results
US 2019/0338000 A1Published application
Cell-permeable (icp)-socs3 recombinant protein and uses thereof
AssigneeCellivery Therapeutics, Inc.
InventorDaewoong JO
Life of this patent
Estimating the term…
Abstract
Provided are an improved cell-permeable (iCP)-SOCS3 recombinant protein and uses thereof. Suppressor of cytokine signaling-3 (SOCS3) is an endogenous protein inhibitor of JAK/STAT pathway, and an aberrant expression of SOCS3 protein was observed in human solid tumors including gastric, colorectal and breast cancer, and glioblastoma. The iCP-SOCS3 recombinant protein provided herein may be used as protein-based anti-lung cancer agent by utilizing the platform technology for macromolecule intracellular transduction.
Claims8
A method of treating lung cancer in a subject in need thereof comprising:
- administering to the subject a therapeutically effective amount of an iCP-SOCS3 recombinant protein,
- wherein the iCP-SOCS3 recombinant protein comprises a SOCS3 protein, an advanced macromolecule transduction domain (aMTD) and a solubilization domain (SD), and the iCP-SOCS3 recombinant protein is represented by following structural formula:
- A-B-C,
- wherein A is the aMTD,
- B is the SOCS3 protein, and
- C is the SD,
- wherein the aMTD has an amino acid sequence of SEQ ID NO:
- 122, and the SD has an amino acid sequence independently selected from the group consisting of SEQ ID NOs:
- 798, 799, 800, 801, 802, 803, and 804.
6 more elements
Dependencies are inferred from the claim text.